Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.59 |
| ▸ | CA2 | P00918 | 5/20 | 0.59 |
| ▸ | CA12 | O43570 | 4/20 | 0.59 |
| ▸ | CA7 | P43166 | 4/20 | 0.59 |
| ▸ | CA9 | Q16790 | 4/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.59 |
| ▸ | ESR1 | P03372 | 2/20 | 0.57 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.56 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.54 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.50 |
| ▸ | LMNA | P02545 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | MAOA | P21397 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | STS | P08842 | 1/20 | 0.47 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.46 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30016425 | 1.00 | CA1 (0.59) | CA1CA2CA12CA7CA9 | |
| SCHEMBL30812164 | 0.87 | ESR1 (0.72) | CA1CA2CA12CA7CA9 | |
| SCHEMBL2543424 | 0.87 | ESR1 (0.72) | CA1CA2CA12CA7CA9 | |
| SCHEMBL28659596 | 0.84 | CA12 (0.63) | CA1CA2CA12CA7CA9 | |
| SCHEMBL6399400 | 0.84 | KMT2A (0.51) | ESR1LMNAMEN1KMT2AKDM4E | |
| SCHEMBL29644794 | 0.83 | ERN1 (0.63) | CA1CA2CA12CA7CA9 | |
| SCHEMBL27507237 | 0.83 | ERN1 (0.63) | CA1CA2CA12CA7CA9 | |
| SCHEMBL31347271 | 0.82 | CA1 (0.59) | CA1CA2CA12CA7CA9 | |
| SCHEMBL6939271 | 0.82 | CA12 (0.59) | CA1CA2CA12CA7CA9 | |
| SCHEMBL1965326 | 0.82 | CA1 (0.73) | CA1CA2CA12CA7CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240217992-A1 | RETINOIC ACID RECEPTOR AGONIST, PREPARATION METHOD THEREFOR, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE | Jiangxi Kerui Pharmaceutical Co., Ltd. (CN) | 2024-07-04 | — | — | US | disclosed |
| US-20240217992-A1 | RETINOIC ACID RECEPTOR AGONIST, PREPARATION METHOD THEREFOR, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE | Jiangxi Kerui Pharmaceutical Co., Ltd. (CN) | 2024-07-04 | — | — | US | disclosed |
| US-20240217992-A1 | RETINOIC ACID RECEPTOR AGONIST, PREPARATION METHOD THEREFOR, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE | Jiangxi Kerui Pharmaceutical Co., Ltd. (CN) | 2024-07-04 | — | — | US | disclosed |
| EP-4332108-A1 | RETINOIC ACID RECEPTOR AGONIST, PREPARATION METHOD THEREFOR, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE | Jiangxi Kerui Pharmaceutical Co., Ltd. (CN) | 2024-03-06 | — | — | EP | disclosed |
| WO-2022228409-A1 | RETINOIC ACID RECEPTOR AGONIST, PREPARATION METHOD THEREFOR, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE | 上海旭成医药科技有限公司 | 2022-11-03 | — | — | WO | disclosed |
| CN-115246856-A | Retinoic acid receptor agonist, preparation method, intermediate, pharmaceutical composition and application thereof | 上海旭成医药科技有限公司 | 2022-10-28 | — | — | CN | disclosed |
| US-8470871-B2 | Ligands that modulate RAR receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-06-25 | — | — | US | disclosed |
| US-8362082-B2 | Biphenyl compound selective agonists of gamma RAR receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-01-29 | — | — | US | disclosed |
| US-8362082-B2 | Biphenyl compound selective agonists of gamma RAR receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-01-29 | — | — | US | disclosed |
| US-8362082-B2 | Biphenyl compound selective agonists of gamma RAR receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2013-01-29 | — | — | US | disclosed |
| US-20090036536-A1 | Biphenyl compound selective agonists of gamma RAR receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-02-05 | — | — | US | disclosed |
| US-20090036536-A1 | Biphenyl compound selective agonists of gamma RAR receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-02-05 | — | — | US | disclosed |
| US-20090023811-A1 | Biphenyl compound selective agonists of gamma RAR receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-01-22 | — | — | US | disclosed |
| US-20090023811-A1 | Biphenyl compound selective agonists of gamma RAR receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-01-22 | — | — | US | disclosed |
| US-20090023811-A1 | Biphenyl compound selective agonists of gamma RAR receptors | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2009-01-22 | — | — | US | disclosed |
| US-20080015246-A1 | Novel ligands that modulate RAR receptors and pharmaceutical/cosmetic compositions comprised thereof | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2008-01-17 | — | — | US | disclosed |
| EP-1831149-A1 | NOVEL LIGANDS THAT MODULATE RAR RECEPTORS AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-09-12 | — | — | EP | disclosed |
| WO-2007068580-A1 | BIPHENYL DERIVATIVES AS SELECTIVE AGONISTS OF GAMMA RAR RECEPTOR | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-06-21 | — | — | WO | disclosed |
| WO-2007068579-A1 | BIPHENYL DERIVATIVES AS SELECTIVE AGONISTS OF GAMMA RAR RECEPTORS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2007-06-21 | — | — | WO | disclosed |
| WO-2006066978-A1 | NOVEL LIGANDS THAT MODULATE RAR RECEPTORS, AND USE THEREOF IN HUMAN MEDICINE AND IN COSMETICS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2006-06-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023811-A1 | Biphenyl compound selective agonists of gamma RAR receptors | RARG, RARB, RARA | CA1 4849/4885CA2 4779/4885CA12 4816/4885 |
| US-20240217992-A1 | RETINOIC ACID RECEPTOR AGONIST, PREPARATION METHOD THEREFOR, INTERMEDIATE, PHARMACEUTICAL COMPOSITION AND USE | RARA, RARG, RXRG | CA1 4533/4885CA2 4249/4885CA12 3640/4885 |
| US-20080015246-A1 | Novel ligands that modulate RAR receptors and pharmaceutical/cosmetic compositions comprised thereof | RARB, RARA, RARG | CA1 4609/4885CA2 4037/4885CA12 4084/4885 |
| US-20090036536-A1 | Biphenyl compound selective agonists of gamma RAR receptors | RARG, RARB, RARA | CA1 4849/4885CA2 4779/4885CA12 4816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.